ACOG: Similar VTE Risk with Vaginal Ring and Combined Oral Contraceptive
When used under routine conditions, vaginal ring and combined oral contraceptives have similar venous thrombolism risks, according to a prospective, controlled, non-interventional cohort study.
When used under routine conditions, vaginal ring (VR) and combined oral contraceptives (COC) have similar venous thrombolism (VTE) risks, according to a prospective, controlled, non-interventional cohort study.
The “Transantlatntic Active Surveillance on Cardiovascular Safety of NuvaRing” (TASC) included 33,704 subjects from the United States and five European countries, and investigated the risks of short and long-term use of VR and COCs in a population representative of routine use.
One cohort used a VR containing etonogestrel and ethinylestradiol. A second cohort used COCs. All subjects were new users-starters, switchers or restarters-and were recruited by 1,661 study centers with a two- to four-year follow-up. Self-reported outcomes were verified by health care professionals. Analysis adjustments were made using the Cox regression model.
Results, presented by Juergen Dinger, MD, PhD, of the Berlin Center for Epidemiology at the American Congress of Obstetricians and Gynecologists’ Annual Clinical Meeting, are based on 46,806 woman-years (WY) of follow-up. Comprehensive measures were taken to ensure a low follow-up loss. Overall, 34 confirmed VTEs occurred in current users of VR or COCs.
The overall VTE incidence for users of hormonal contraceptives is 9.4/10,000 WY, respectively (95% confidence interval [CI], 6.5-13.1). For VR and COCs, the VTE incidence is 8.8 and 9.9/10,000 WY, respectively.
The crude hazard ratio for VR vs. COCs is 0.9 (95% CI: 6.5-13.1). After making allowances for age, body mass index, duration of current VR/COC use and family history of VTE, the adjusted HR is 0.8 (95% CI: 0.4-1.6).
Results indicate a similar risk of VTE for users of VR or COC under conditions of routine use.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More
